Public Comment
ASTRO posts drafts of clinical practice guidelines, white papers and other documents for public comment before they are finalized and sent to ASTRO's Board of Directors for approval. The public comment period is an integral part of guidance development, and is preceded by a series of reviews and revisions and may be followed by a final peer review if the document is submitted to a journal for publication. ASTRO encourages those in the radiation oncology field to comment and then share with colleagues, producing a more robust public response.
Practice Parameters for the Performance of Radionuclide-based High-dose-rate Brachytherapy and Transperineal Permanent Brachytherapy of Prostate Cancer
These practice parameters were collaboratively revised by the American College of Radiology (ACR), American Brachytherapy Society (ABS) and ASTRO. The documents were reviewed by the ACR expert panels, which included radiation oncologists. It is important that recommendations propose specific language to amend the documents. To log your recommendations for these documents, please send them to Lisa Bradfield or contact her with any questions. The comment period ends October 18, 2019.
Management of Hereditary Breast Cancer: an ASCO/ASTRO/SSO Guideline
The guideline focuses on patients with BRCA 1/2 or moderate-penetrance germline mutations and addresses the role of contralateral prophylactic mastectomy, adjuvant radiation therapy, and breast conserving surgery with radiotherapy versus mastectomy. It also make recommendations on the role of platinum systemic therapy and PARP inhibitors in this population for both early- and late-stage breast cancer.
To participate, interested reviewers can download the confidentiality agreement and email a signed copy to guidelines@asco.org to receive access to the survey containing the guideline recommendations. The comment period is October 3-17, 2019.